Prime Medicine, Inc. (PRME) Tops Q3 EPS by 5c

Prime Medicine, Inc. (NASDAQ: PRME) reported Q3 EPS of ($0.44), $0.05 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $210 thousand versus the consensus estimate of $0 .

For earnings history and earnings-related data on Prime Medicine, Inc. (PRME) click here.

You May Also Be Interested In

• SpaceX (SPCX) gains nearly 6% as traders follow the money
• Singapore exports surge 40.6% in July on electronics demand
• SpaceX (SPCX) call put ratio 1.7 calls to 1 put as share price up 5%